

		Frontline / Untreated	Relapse/ Refractory
Hodgkin's Lymphoma		<p>No trials available</p> <p>Open: AHOD2131 (PI: Grover SC: Cook) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma</p> <p>Pending EA5211 (chemo vs chemo + pembrolizumab prior to transplant)</p>	<p>Open: LCCC-1606: (PI: Grover) CD30 + CCR4 CAR-T for R/R CD30+ HL and CTCL CART POD</p> <p>LCCC 1852: (PI: Grover) PD-1 inhibitors after CD30-CAR-T in R/R HL (3+ prior lines) CART POD</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>Pending AFM13-203: (PI: Grover) A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma CART POD</p>
Non- Hodgkin' s Lymphoma	DLBCL	<p>Open:</p> <p>S1918: (PI: Beaven SC: Cook) Age 75 or older, eligible lymphoma subtypes include: DLBCL (NOS), DLBCL (GCB), DLBCL (ABC), THRBCL, primary cutaneous DLBCL, leg type, Intravascular large B cell lymphoma, EBV+ DLBCL (NOS), DLBCL associated with chronic inflammation, HHV8+ DLBCL (NOS), High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, High grade B-cell lymphoma (NOS), Follicular lymphoma grade 3b. Must not have known lymphomatous involvement of the CNS.</p>	<p>Open: LCCC 2033- (PI: Dittus SC: Cook) Polatuzumab vedotin + RGDP for 1st relapse DLBCL (potential bridge to ASCT or CAR-T)</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>LCCC 1811: (PI: Grover) kappa- directed CAR-T cells for kappa-restricted R/R aggressive and indolent lymphomas and CLL/SLL) CART POD</p> <p>LCCC-1813: (PI: Grover) anti-CD19 CAR-T with inducible CAS-9 safety switch for R/R B-cell lymphoma CART POD</p> <p>AC676: (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p> <p>Pending</p>
	FL	<p>Open:</p>	<p>Open:</p>

		<p>R1979-HM-2298 (OLYMPIA-1) (PI: Grover SC: Cook) (bispecific antibody vs investigator choice chemo in untreated FL)</p>	<p>LCCC 2033-(PI: Dittus SC: Cook)- Polatuzumab vedotin + RGDP for 1st relapse DLBCL (potential bridge to ASCT or CAR-T)</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>LCCC 1811: (PI: Grover) kappa- directed CAR-T cells for kappa-restricted R/R aggressive and indolent lymphomas and CLL/SLL) CART POD</p> <p>LCCC-1813: (PI: Grover) anti-CD19 CAR-T with inducible CAS-9 safety switch for R/R B-cell lymphoma CART POD</p> <p>AC676 (Suspended): (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p> <p><u>Pending</u></p>
<p>MZL</p>	<p>No trials available</p>		<p><u>Open:</u></p> <p>LCCC 2033(PI: Dittus SC: Cook)-- Polatuzumab vedotin + RGDP for 1st relapse DLBCL (potential bridge to ASCT or CAR-T)</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>LCCC 1811: (PI: Grover) kappa- directed CAR-T cells for kappa-restricted R/R aggressive and indolent lymphomas and CLL/SLL) CART POD</p> <p>LCCC-1813: (PI: Grover) anti-CD19 CAR-T with inducible CAS-9 safety switch for R/R B-cell lymphoma CART POD</p> <p>AC676: (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p> <p><u>Pending</u></p>

	<p>MCL</p>	<p><u>Open:</u></p> <p>A052101: (PI: Beaven SC: Cook) Zanubrutinib for older/ non-transplant patients with untreated MCL</p>	<p><u>Open:</u></p> <p>LCCC 2033 (PI: Dittus SC: Cook)- Polatuzumab vedotin + RGDP for 1st relapse DLBCL (potential bridge to ASCT or CAR-T)</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>LCCC 1811: (PI: Grover) kappa- directed CAR-T cells for kappa-restricted R/R aggressive and indolent lymphomas and CLL/SLL) CART POD</p> <p>LCCC-1813: (PI: Grover) anti-CD19 CAR-T with inducible CAS-9 safety switch for R/R B-cell lymphoma CART POD</p> <p>AC676: (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p> <p><u>Pending</u></p>
	<p>WM</p>	<p>No trials available</p>	<p><u>Open:</u></p> <p>LCCC 2033- (PI: Dittus SC: Cook) Polatuzumab vedotin + RGDP for 1st relapse DLBCL (potential bridge to ASCT or CAR-T)</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY, CART POD</p> <p>LCCC 1811: (PI: Grover) kappa- directed CAR-T cells for kappa-restricted R/R aggressive and indolent lymphomas and CLL/SLL) CART POD</p> <p>LCCC-1813: (PI: Grover) anti-CD19 CAR-T with inducible CAS-9 safety switch for R/R B-cell lymphoma CART POD</p> <p>AC676: (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p>

		Pending
PCNSL or SCNSL	<p>Open:</p> <p>A051901 (PI: Dittus SC: Cook) - Methotrexate, Ritux, Lenalidomide and Nivo (Nivo-MR2) followed by Len and Nivo maintenance in PCNSL.</p>	<p>Open:</p> <p>LCCC 1841: (PI: Dittus SC: Cook) Acalabrutinib in R/R PCNSL or SCNSL</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY</p>
T-Cell	<p>Open:</p> <p>A051902: (PI: Beaven SC: Cook) Histologically confirmed diagnosis of PTCL with <10% CD30 expression by immunohistochemistry. Measurable disease as defined by the Lugano criteria. No prior systemic therapy or radiation therapy for T-cell lymphoma (excluding corticosteroids). Patients with known central nervous system involvement are excluded</p>	<p>Open:</p> <p>LCCC-1606: (PI: Grover) CD30 + CCR4 CAR-T for R/R CD30+ HL and CTCL</p> <p>LCCC 1904: (PI: Beaven) CD30 CAR-T for R/R CD30+ T-cell lymphoma</p> <p>LCCC-1532: (PI: Beaven) CD30 CAR-T for CD30+ R/R HL or NHL (2 + lines of prior therapy); PEDS ONLY</p> <p>Pending</p> <p>AFM13-203: (PI: Grover) A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma CART POD</p>
PTLD	<p>Open:</p> <p>OSU-22114- (PI: Dittus SC: Erskine) Phase 2 Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder</p>	No trials available
Chronic Lymphocytic Leukemia	<p>Open:</p> <p>S1925: (PI: Jensen SC: Cook) A Randomized, Phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with CLL: EVOLVE CLL Study.</p>	<p>Open:</p> <p>AC676 (SUSPENDED): (PI: Stevens SC: Erskine) A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-malignancy activity of AC676 in patients with R/R B-cell malignancies</p>

	<p>BGB-11417-301(PI: Stephens SC: Cook) A Phase 3, Open-label, Randomized Study of BGB-11417 plus Zanubrutinib compared with Venetoclax plus Obinutuzumab in patients with previously untreated CLL or SLL.</p> <p><u>Pending</u></p>	<p><u>Pending</u> LP-168-USI01: (PI: Jensen SC: TBD) A study of oral administration of LP-168 in patients with relapsed or refractory B-cell malignancies.</p>
<p>Translational</p>	<p><u>Open:</u></p> <p>LCCC 1850: (PI: Jensen SC: McCarthy) Registry for Adults with Lymphoma</p> <p>17-3193: (PI: Beaven SC: McCarthy) USCLC National Cutaneous Lymphoma Registry</p>	
<p>Coordinator Contact Info</p>	<p><u>Lymphoma POD:</u> Tammy Cook: pager (919)216-5561 Amber Erskine: pager (919) 393-0593 Ryan Sutterby: pager TBD Devin McCarthy: phone (919)-445-4852 <u>CAR-T:</u> Kelly Hoye: pager 919- 216-6371</p>	